Protective Immunity To Ebola And Marburg Viral Infections Using A Venezuelan Equine Encephalitis Virus Replicon Expressing Filovirus Glycoproteins | 3282
Journal of Clinical & Cellular Immunology
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Infection with filoviruses causes a severe disease accompanied by high mortality rates. While there are several vaccine
platforms being evaluated, there are no licensed vaccines or therapies available for human use. A vaccine approach utilizing
Venezuelan equine encephalitis virus (VEE) replicons expressing filovirus proteins was the first vaccine approach that provided
complete protection against Marburg infection in non-human primates (Hevey, et al. 1998). We have previously presented data
on the utility of VEE replicons expressing the glycoprotein, nucleoprotein, VP24, VP30, VP35, and VP40 to protect against
Ebola Zaire challenge in mice and non-human primates by various routes of administration. Protective efficacy using a vaccine
that expresses the glycoprotein of the homologous virus strain has been achieved in both cynomolgus and rhesus macaque
virus challenge models. To date, we have determined that the VEE replicon platform is efficacious against multiple species of
Ebolavirus and strains of Marburgvirus using an accelerated single dose regiment. Current studies are focused on the ability to
provide pan-Ebola and pan-Marburg protection through mixing of various VEE replicons, on the impact of anti-vector responses
on immunogenicity and protective efficacy, durability, and on the search for a correlate of immunity. The data demonstrates
that VEE replicons expressing Ebola or Marburg virus glycoproteins are capable of inducing immunity against Filoviruses in the
relevant non-human primate models and warrant further evaluation as a human use vaccine.
Dr. Olinger is the principle investigator of several projects focused on the development of countermeasures against highly lethal viral hemorrhagic
fever viruses (VHFV). Dr. Olinger?s team has been working on the development of vaccines, immunotherapic approaches, and small molecule
antiviral discovery for VHFV and Alphaviruses. Dr. Olinger has a Ph.D. in immunology and virology from Rush University in Chicago, IL and was
awarded a post-doctoral research fellow with the National Research Council working at USAMRIID. Dr. Olinger has served as a subject matter
expert for multiple DOD and Federal panels related to biodefense and serves as an NIH reviewer.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals